Innate immune mediators in cancer: between defense and resistance (Q38991015)

8 September 2017

1 reference

title

Innate immune mediators in cancer: between defense and resistance (English)

1 reference

8 September 2017

6

1 reference

8 September 2017

Ignacio Melero, MD-PhD

5

object named as

Ignacio Melero

1 reference

8 September 2017

Pedro Berraondo

1

1 reference

8 September 2017

Luna Minute

2

1 reference

8 September 2017

Daniel Ajona

3

1 reference

8 September 2017

Leticia Corrales

4

1 reference

8 September 2017

1 November 2016

1 reference

8 September 2017

Immunological Reviews

1 reference

8 September 2017

274

1 reference

8 September 2017

1

1 reference

8 September 2017

290-306

1 reference

Complement System Part I - Molecular Mechanisms of Activation and Regulation

8 September 2017

1 reference

Complement: a key system for immune surveillance and homeostasis

21 January 2018

1 reference

Complement System Part II: Role in Immunity

21 January 2018

1 reference

C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity

21 January 2018

1 reference

C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease

21 January 2018

1 reference

Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice

21 January 2018

1 reference

Complement in immune and inflammatory disorders: therapeutic interventions

21 January 2018

1 reference

Complement, a target for therapy in inflammatory and degenerative diseases.

21 January 2018

1 reference

The role of the anaphylatoxins in health and disease

21 January 2018

1 reference

Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo

21 January 2018

1 reference

Pivotal advance: The pattern recognition receptor ligands lipopolysaccharide and polyinosine-polycytidylic acid stimulate factor B synthesis by the macrophage through distinct but overlapping mechanisms

21 January 2018

1 reference

Role of complement in induction of antibody production in vivo. Effect of cobra factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses

21 January 2018

1 reference

Immune Response of a Patient with Deficiency of the Fourth Component of Complement and Systemic Lupus Erythematosus

21 January 2018

1 reference

T cell-dependent immune response in C1q-deficient mice: defective interferon gamma production by antigen-specific T cells

21 January 2018

1 reference

C3d of complement as a molecular adjuvant: bridging innate and acquired immunity

21 January 2018

1 reference

The role of the CD19/CD21 complex in B cell processing and presentation of complement-tagged antigens

21 January 2018

1 reference

Human complement C3 deficiency: Th1 induction requires T cell-derived complement C3a and CD46 activation.

21 January 2018

1 reference

C3 opsonization regulates endocytic handling of apoptotic cells resulting in enhanced T-cell responses to cargo-derived antigens

21 January 2018

1 reference

Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells

21 January 2018

1 reference

Absence of signaling into CD4⁺ cells via C3aR and C5aR enables autoinductive TGF-β1 signaling and induction of Foxp3⁺ regulatory T cells.

21 January 2018

1 reference

The role of complement in CD4⁺ T cell homeostasis and effector functions

21 January 2018

1 reference

Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype

21 January 2018

1 reference

The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo

21 January 2018

1 reference

Complement C4 maintains peripheral B-cell tolerance in a myeloid cell dependent manner.

21 January 2018

1 reference

Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells

21 January 2018

1 reference

The role of complement in tumor growth

21 January 2018

1 reference

Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer.

21 January 2018

1 reference

Modulation of the antitumor immune response by complement

21 January 2018

1 reference

Complement activation in astrocytomas: deposition of C4d and patient outcome

21 January 2018

1 reference

Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer.

21 January 2018

1 reference

Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma.

21 January 2018

1 reference

Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancer

21 January 2018

1 reference

Increased activity of the mannan-binding lectin complement activation pathway in patients with colorectal cancer.

21 January 2018

1 reference

Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway

21 January 2018

1 reference

STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity

21 January 2018

1 reference

Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation

21 January 2018

1 reference

STING is a direct innate immune sensor of cyclic di-GMP

21 January 2018

1 reference

STING and the innate immune response to nucleic acids in the cytosol

21 January 2018

1 reference

STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling

21 January 2018

1 reference

Smoldering and polarized inflammation in the initiation and promotion of malignant disease

21 January 2018

1 reference

Immunosuppressive networks in the tumour environment and their therapeutic relevance

21 January 2018

1 reference

Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement.

21 January 2018

1 reference

Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors.

21 January 2018

1 reference

Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA

21 January 2018

1 reference

A very sensitive coupled luminescent assay for cytotoxicity and complement-mediated lysis

21 January 2018

1 reference

Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1.

21 January 2018

1 reference

Complement factor H is elevated in bronchoalveolar lavage fluid and sputum from patients with lung cancer

21 January 2018

1 reference

Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells.

21 January 2018

1 reference

Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer

21 January 2018

1 reference

Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy.

21 January 2018

1 reference

Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients

21 January 2018

1 reference

Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth

21 January 2018

1 reference

Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression.

21 January 2018

1 reference

Complement c5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche

21 January 2018

1 reference

Pulmonary alveolar macrophages contribute to the premetastatic niche by suppressing antitumor T cell responses in the lungs

21 January 2018

1 reference

Complement 5a Enhances Hepatic Metastases of Colon Cancer via Monocyte Chemoattractant Protein-1-mediated Inflammatory Cell Infiltration

21 January 2018

1 reference

Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization

21 January 2018

1 reference

Opposing roles for complement component C5a in tumor progression and the tumor microenvironment

21 January 2018

1 reference

Overexpression of CD88 predicts poor prognosis in non-small-cell lung cancer

21 January 2018

1 reference

Influence of the C5a-C5a receptor system on breast cancer progression and patient prognosis

21 January 2018

1 reference

Autocrine effects of tumor-derived complement.

21 January 2018

1 reference

Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88).

21 January 2018

1 reference

C5a receptor enhances hepatocellular carcinoma cell invasiveness via activating ERK1/2-mediated epithelial-mesenchymal transition

21 January 2018

1 reference

Complement activation promotes colitis-associated carcinogenesis through activating intestinal IL-1β/IL-17A axis.

21 January 2018

1 reference

Early neoplastic progression is complement independent

21 January 2018

1 reference

Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice.

21 January 2018

1 reference

cC1qR/CR and gC1qR/p33: observations in cancer

21 January 2018

1 reference

C1q as a unique player in angiogenesis with therapeutic implication in wound healing

21 January 2018

1 reference

C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation

21 January 2018

1 reference

PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer

21 January 2018

1 reference

Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack.

21 January 2018

1 reference

New perspectives on complement mediated immunotherapy

21 January 2018

1 reference

Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer

21 January 2018

1 reference

Complement inhibition in cancer therapy

21 January 2018

1 reference

Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response

21 January 2018

1 reference

Does the immune system see tumors as foreign or self?

21 January 2018

1 reference

Innate immune recognition

21 January 2018

1 reference

The danger model: a renewed sense of self

21 January 2018

1 reference

Pathogen recognition and innate immunity

21 January 2018

1 reference

STING-dependent cytosolic DNA sensing pathways

21 January 2018

1 reference

Recognition of Endogenous Nucleic Acids by the Innate Immune System

21 January 2018

1 reference

Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway

21 January 2018

1 reference

Structure-Function Analysis of STING Activation by c[G(2′,5′)pA(3′,5′)p] and Targeting by Antiviral DMXAA

21 January 2018

1 reference

Carcinoma-derived interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation

21 January 2018

1 reference

Innate immune recognition of cancer

21 January 2018

1 reference

Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment

21 January 2018

1 reference

Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells

21 January 2018

1 reference

The role of the purinergic P2X7 receptor in inflammation

21 January 2018

1 reference

STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.

21 January 2018

1 reference

STING-mediated DNA sensing promotes antitumor and autoimmune responses to dying cells

21 January 2018

1 reference

Diverse roles of STING-dependent signaling on the development of cancer

21 January 2018

1 reference

IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine

21 January 2018

1 reference

MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18

21 January 2018

1 reference

STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment

21 January 2018

1 reference

Inflammation-driven carcinogenesis is mediated through STING

21 January 2018

1 reference

STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation

21 January 2018

1 reference

Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer

21 January 2018

1 reference

Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid

21 January 2018

1 reference

Anticancer flavonoids are mouse-selective STING agonists.

21 January 2018

1 reference

5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential

21 January 2018

1 reference

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

21 January 2018

1 reference

Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer

21 January 2018

1 reference

A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP

21 January 2018

1 reference

STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer

21 January 2018

1 reference

STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity

21 January 2018

1 reference

In situ vaccination for the treatment of cancer.

21 January 2018

1 reference

Growing tumors induce a local STING dependent Type I IFN response in dendritic cells

21 January 2018

1 reference

TLR ligands in the local treatment of established intracerebral murine gliomas.

21 January 2018

1 reference

LIGHT delivery to tumors by mesenchymal stem cells mobilizes an effective antitumor immune response.

21 January 2018

1 reference

Promoting immune responses by LIGHT in the face of abundant regulatory T cell inhibition.

21 January 2018

1 reference

The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity

21 January 2018

1 reference

Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma

21 January 2018

1 reference

Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice

21 January 2018

1 reference

Regression of established AB1 murine mesothelioma induced by peritumoral injections of CpG oligodeoxynucleotide either alone or in combination with poly(I:C) and CD40 ligand plasmid DNA.

21 January 2018

1 reference

Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation

21 January 2018

1 reference

Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice

21 January 2018

1 reference

Intratumoral injection of lipopolysaccharide causes regression of subcutaneously implanted mouse glioblastoma multiforme.

21 January 2018

1 reference

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study

21 January 2018

1 reference

Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans

21 January 2018

1 reference

The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes.

21 January 2018

1 reference

Innate lymphoid cells: parallel checkpoints and coordinate interactions with T cells.

21 January 2018

1 reference

Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells

21 January 2018

1 reference

NKG2D function protects the host from tumor initiation

21 January 2018

1 reference

Functions of natural killer cells

21 January 2018

1 reference

Receptors for HLA class-I molecules in human natural killer cells.

21 January 2018

1 reference

HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A

21 January 2018

1 reference

MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells

21 January 2018

1 reference

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

21 January 2018

1 reference

KIR: diverse, rapidly evolving receptors of innate and adaptive immunity

21 January 2018

1 reference

Tumor and viral recognition by natural killer cells receptors

21 January 2018

1 reference

The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans

21 January 2018

1 reference

NKG2D Receptor and Its Ligands in Host Defense

21 January 2018

1 reference

Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.

21 January 2018

1 reference

NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy

21 January 2018

1 reference

Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer.

21 January 2018

1 reference

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

21 January 2018

1 reference

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

Role of the complement system in NK cell-mediated antitumor T-cell responses

21 January 2018

1 reference

Transient complement inhibition promotes a tumor-specific immune response through the implication of natural killer cells

21 January 2018

1 reference

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

21 January 2018

1 reference

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

21 January 2018

1 reference

Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers.

21 January 2018

1 reference

Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'

21 January 2018

1 reference

Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma

21 January 2018

1 reference

Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors.

21 January 2018

1 reference

Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice.

21 January 2018

1 reference

Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade

21 January 2018

1 reference

Differential effects of interleukin-15 and interleukin-2 on differentiation of bipotential T/natural killer progenitor cells

21 January 2018

1 reference

Safety and immunologic effects of IL-15 administration in nonhuman primates

21 January 2018

1 reference

Distinctions in lymphocyte responses to IL-2 and IL-15 reflect differential ligand binding interactions with the IL-2Rbeta chain and suggest differential roles for the IL-2Ralpha and IL-15Ralpha subunits

21 January 2018

1 reference

Autocrine and/or paracrine growth of adult T-cell leukaemia tumour cells by interleukin 15.

21 January 2018

1 reference

Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer

21 January 2018

1 reference

IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization

21 January 2018

1 reference

The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas

21 January 2018

1 reference

Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein.

21 January 2018

1 reference

21 January 2018

The complexity of HDL.

1 reference

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

21 January 2018

1 reference

Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate

21 January 2018

1 reference

Selenite induces posttranscriptional blockade of HLA-E expression and sensitizes tumor cells to CD94/NKG2A-positive NK cells.

21 January 2018

1 reference

Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens.

21 January 2018

1 reference

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

21 January 2018

1 reference

Targeting CD137 enhances the efficacy of cetuximab.

21 January 2018

1 reference

Natural innate and adaptive immunity to cancer

21 January 2018

1 reference

The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity

21 January 2018

1 reference

HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment

21 January 2018

1 reference

Myeloid-derived suppressor cells as regulators of the immune system

21 January 2018

1 reference

Mechanism of T cell tolerance induced by myeloid-derived suppressor cells.

21 January 2018

1 reference

Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation

21 January 2018

1 reference

Tumour-educated macrophages promote tumour progression and metastasis

21 January 2018

1 reference

Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancer

21 January 2018

1 reference

Immune tolerance to tumor antigens occurs in a specialized environment of the spleen

21 January 2018

1 reference

Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells.

21 January 2018

1 reference

Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells

21 January 2018

1 reference

CSF-1/CSF-1R targeting agents in clinical development for cancer therapy.

21 January 2018

1 reference

Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins.

21 January 2018

1 reference

Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8.

21 January 2018

1 reference

Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs).

21 January 2018

1 reference

Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients.

21 January 2018

1 reference

Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas

21 January 2018

1 reference

Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells

21 January 2018

1 reference

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

21 January 2018

1 reference

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes

21 January 2018

1 reference

The current status of cancer biomarker research using tumour-associated antigens for minimal invasive and early cancer diagnostics

21 January 2018

1 reference

B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis

21 January 2018

1 reference

De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent

21 January 2018

1 reference

FcRgamma activation regulates inflammation-associated squamous carcinogenesis.

21 January 2018

1 reference

B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas

21 January 2018

1 reference

IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia

21 January 2018

1 reference

Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.

21 January 2018

1 reference

PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression.

21 January 2018

1 reference

CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer

21 January 2018

1 reference

Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies

21 January 2018

1 reference

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

21 January 2018

1 reference

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

Microbiome and Anticancer Immunosurveillance

21 January 2018

1 reference

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

21 January 2018

1 reference

Complement Factor H as a Marker for Detection of Bladder Cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/IMR.12464

1 reference

8 September 2017

1 reference